COPD treatment: What you need to know about important PBS changes
This content is independently produced by Australian Doctor Group, made possible with a grant from Novartis and Boehringer Ingelheim.
Inappropriate prescribing of some combination therapy respiratory medicines has led to significant changes to PBS recommendations.
Sparked by a recent PBAC review, the changes are designed to bring prescribing practices into line with clinical guidelines, particularly on the treatment and management of moderate to severe COPD.
Effective now, they include new restrictions on inhaled corticosteroids (ICS) use.
Notably, ICS and long-acting B2 adrenergic receptor agonist (LABA) combinations have had their restriction level